<DOC>
	<DOCNO>NCT00889421</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Apremilast treatment uveitis .</brief_summary>
	<brief_title>Apremilast Treatment Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>patient visionthreatening autoimmune uveitis failure respond prednisone least one systemic immunosuppressive , intolerance medication due side effect serious concomitant illness could interfere subject 's participation previous current use alkylating agent use CYP3A4 inhibitor trial TNF blocker use within 8 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>uveitis</keyword>
	<keyword>apremilast</keyword>
</DOC>